Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus.

Nomura, Shosaku; Shouzu, Akira; Taniura, Takehito; Okuda, Yoshinori; Omoto, Seitaro; Suzuki, Masahiko; Ito, Tomoki; Toyoda, Nagaoki

Nomura, Shosaku; Shouzu, Akira; Taniura, Takehito; Okuda, Yoshinori; Omoto, Seitaro; Suzuki, Masahiko; Ito, Tomoki; Toyoda, Nagaoki.

Afiliación

Nomura S; Center of Thrombosis and Hemostasis, Kansai Medical University Medical Center, Moriguchi, Japan.
Shouzu A; Division of Diabetes, Saiseikai Izuo Hospital, Osaka, Japan.
Taniura T; Division of Internal Medicine, Daiwa Hospital, Osaka, Japan.
Okuda Y; Division of Internal Medicine, Meisai Kinen Hospital, Osaka, Japan.
Omoto S; Division of Internal Medicine, Yukeikai Hospital, Neyagawa, Japan.
Suzuki M; Division of Internal Medicine, Katano Hospital, Katano, Japan.
Ito T; First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Toyoda N; Second Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.

Clin Pharmacol ; 15: 41-55, 2023.

Article en En | MEDLINE | ID: mdl-37255963

Palabras clave

anagliptin; atherosclerosis; soluble LOX-1; tofogliflozin; type 2 diabetes mellitus

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google